SPORE PEPTIDOGLYCAN SYNTHESIS IN BACILLUS SUBTILIS

在过去的十年里，淋病的发病率有所下降。 与这种下降趋势形成鲜明对比的是，菌株所占比例 显示抗药性有所增加。青霉素耐药菌株 1976年首次报道，从那时起，抗药性 来自世界各地的淋病奈瑟菌分离株有 都被描述过。尽管一些喹诺酮类药物和超广谱药物 头孢菌素类药物目前被证明足以用于一种治疗方案， 物种的脆弱性可能会减少并具有抗菌性 抵抗只是个时间问题。生理适应性和 逃避免疫宿主反应有助于微生物的持久性 这些策略中的许多都可以通过和通过 外表面低聚糖(LOS)的组成。最重要的是 可能相关的是可证明的抗原变异和 寡糖(OS)的异质性。对重要部分透明 这些差异之一是mAb2C7，它识别OS表位 这是在体内广泛表达的。更好地理解 2C7的反应性的结构特征可以提供改进的 淋球菌疫苗开发的基础。在这次调查中， 利用几个已知的和一个未知的LO，我们正在执行他们的 使用简单的化学操作和结构表征 电喷雾电离的质谱学技术 碰撞诱导分解串联质谱仪。

The incidence of gonorrhea has decreased during the last decade. In stark contrast to this downward trend, the proportion of strains showing drug resistance has increased. Penicillin resistant strains were first reported in 1976 and, since that time, drug resistant Neisseria gonorrhoeae isolates from various parts of the world have been described. Although some quinolones and extended-spectrum cephalosporins are currently proving adequate for a treatment regimen, species vulnerability will likely diminish and antimicrobial resistance is a matter of time. Physiological adaptability and evasion of immune host response contribute to microbial persistence and many of these strategies can be manifested through and by the components of the outer surface Hpooligosaccharide (LOS). Foremost, and probably related, are the demonstrable antigenic variations and oligosaccharide (OS) heterogeneity. Transparent to a significant part of these differences is the mAb 2C7, which recognizes an OS epitope that is widely expressed in vivo. A better understanding of the structural features of reactivity for 2C7 may provide an improved basis for gonococcal vaccine development. In this investigation, using several known andone unknown LOS, we are carrying out their structural characterization using simple chemical manipulations and the mass spectrometry techniques of electrospray ionization, collision-induced decomposition tandem mass spectrometry.